{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:33Z","timestamp":1787020533070,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1\/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target.\u00a0There are many reasons of this, including physicians\u2019 inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowering drugs, that not only allow for the effective reduction of LDL-C and do not increase the risk of new onset diabetes (NOD), and\/or glucose impairment; in the opposite, some of them might effectively improve glucose control. One of the most interesting is pitavastatin, which is now available in Europe, with the best metabolic profile within statins (no risk of NOD, improvement of fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with the potential for the reduction of NOD risk), innovative therapies\u2014PCSK9 inhibitors and inclisiran with no DMT2 risk increase, and new forthcoming therapies, including apabetalone and obicetrapib\u2014for the latter one with the possibility of even decreasing the number of patients diagnosed with prediabetes and DMT2. Altogether, nowadays we have possibility to individualize lipid lowering therapy in DMT2 patients and increase the number of patients on LDL-C goal without any risk of new onset diabetes and\/or diabetes control worsening, and in consequence to reduce the risk of CVD complications due to progression of atherosclerosis in this patients\u2019 group.<\/jats:p>","DOI":"10.1186\/s12933-022-01684-5","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T12:12:53Z","timestamp":1669637573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Personalized management of dyslipidemias in patients with diabetes\u2014it is time for a new approach (2022)"],"prefix":"10.1186","volume":"21","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"Surma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"14790","DOI":"10.1038\/s41598-020-71908-9","volume":"10","author":"X Lin","year":"2020","unstructured":"Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10:14790.","journal-title":"Sci Rep"},{"key":"1684_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"1684_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25\u201332.","journal-title":"Eur J Prev Cardiol"},{"key":"1684_CR4","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"1684_CR5","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s12325-019-00941-6","volume":"36","author":"F Spannella","year":"2019","unstructured":"Spannella F, Giulietti F, Di Pentima C, Sarzani R. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded \u201cdouble-trouble\u201d lipid profile in overweight\/obese. Adv Ther. 2019;36:1426\u201337.","journal-title":"Adv Ther"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/(SICI)1096-9136(199708)14:3+<S25::AID-DIA441>3.0.CO;2-1","volume":"14","author":"HC Gerstein","year":"1997","unstructured":"Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med. 1997;14:25\u201331.","journal-title":"Diabet Med"},{"key":"1684_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2297","volume":"370","author":"X Cai","year":"2020","unstructured":"Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370: m2297.","journal-title":"BMJ"},{"key":"1684_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001776","volume":"9","author":"UP Gujral","year":"2021","unstructured":"Gujral UP, Jagannathan R, He S, Huang M, Staimez LR, Wei J, et al. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021;9: e001776.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-017-0542-6","volume":"16","author":"G de Simone","year":"2017","unstructured":"de Simone G, Wang W, Best LG, Yeh F, Izzo R, Mancusi C, et al. Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol. 2017;16:64.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407\u201318.","journal-title":"N Engl J Med"},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/dc16-2388","volume":"40","author":"KKW Olesen","year":"2017","unstructured":"Olesen KKW, Madsen M, Egholm G, Thim T, Jensen LO, Raungaard B, et al. Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment. Diabetes Care. 2017;40:1103\u201310.","journal-title":"Diabetes Care"},{"key":"1684_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.5114\/aoms.2019.89449","volume":"15","author":"N Katsiki","year":"2019","unstructured":"Katsiki N, Banach M, Mikhailidis DP. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch Med Sci. 2019;15:1357\u201364.","journal-title":"Arch Med Sci"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","volume":"17","author":"M Banach","year":"2021","unstructured":"Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbu\u015b K, et al. PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447\u2013547.","journal-title":"Arch Med Sci"},{"key":"1684_CR14","first-page":"274","volume":"26","author":"N Plana","year":"2014","unstructured":"Plana N, Ibarretxe D, Cabr\u00e9 A, Ruiz E, Masana L. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clin Investig Arterioscler. 2014;26:274\u201384.","journal-title":"Clin Investig Arterioscler"},{"key":"1684_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016947","volume":"10","author":"AD Kaze","year":"2021","unstructured":"Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study. J Am Heart Assoc. 2021;10: e016947.","journal-title":"J Am Heart Assoc"},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet. 2020;396:1644\u201352.","journal-title":"Lancet"},{"key":"1684_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","volume":"131","author":"AM Navar-Boggan","year":"2015","unstructured":"Navar-Boggan AM, Peterson ED, D\u2019Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451\u20138.","journal-title":"Circulation"},{"key":"1684_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/eurheartj\/ehab532","volume":"43","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. How to live to 100 before developing clinical coronary artery disease: a suggestion. Eur Heart J. 2022;43:249\u201350.","journal-title":"Eur Heart J"},{"key":"1684_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43:830\u20133.","journal-title":"Eur Heart J"},{"key":"1684_CR20","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","volume":"166","author":"M Banach","year":"2021","unstructured":"Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, et al. ACS EuroPath Central & South European Countries Project. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499.","journal-title":"Pharmacol Res"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2213-8587(22)00043-2","volume":"10","author":"P Ostadal","year":"2022","unstructured":"Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, ODYSSEY OUTCOMES Investigators, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10:330\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1684_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36802","volume":"4","author":"W Thompson","year":"2021","unstructured":"Thompson W, Morin L, Jarb\u00f8l DE, Andersen JH, Ernst MT, Nielsen JB, et al. Statin discontinuation and cardiovascular events among older people in Denmark. JAMA Netw Open. 2021;4: e2136802.","journal-title":"JAMA Netw Open"},{"key":"1684_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jval.2015.06.002","volume":"18","author":"PK Rannanheimo","year":"2015","unstructured":"Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera J, Korhonen MJ. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health. 2015;18:896\u2013905.","journal-title":"Value Health"},{"key":"1684_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1074248417745357","volume":"23","author":"E Martin-Ruiz","year":"2018","unstructured":"Martin-Ruiz E, Olry-de-Labry-Lima A, Oca\u00f1a-Riola R, Epstein D. Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention. J Cardiovasc Pharmacol Ther. 2018;23:200\u201315.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1684_CR25","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","volume":"40","author":"P Giral","year":"2019","unstructured":"Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516\u201325.","journal-title":"Eur Heart J"},{"key":"1684_CR26","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372.","journal-title":"Eur Heart J"},{"key":"1684_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2021.101127","volume":"84","author":"A Sahebkar","year":"2021","unstructured":"Sahebkar A, Kiaie N, Gorabi AM, Mannarino MR, Bianconi V, Jamialahmadi T, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021;84: 101127.","journal-title":"Prog Lipid Res"},{"key":"1684_CR28","doi-asserted-by":"publisher","first-page":"3987065","DOI":"10.1155\/2020\/3987065","volume":"2020","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, et al. Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;2020:3987065.","journal-title":"Cardiovasc Ther"},{"key":"1684_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12933-022-01524-6","volume":"21","author":"WW Seo","year":"2022","unstructured":"Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol. 2022;21:82.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-019-0969-z","volume":"18","author":"HS Jeong","year":"2019","unstructured":"Jeong HS, Hong SJ, Son S, An H, Kook H, Joo HJ, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol. 2019;18:162.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jdi.12483","volume":"7","author":"CH Huang","year":"2016","unstructured":"Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016;7:769\u201376.","journal-title":"J Diabetes Investig"},{"key":"1684_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.5551\/jat.1719","volume":"16","author":"T Teramoto","year":"2009","unstructured":"Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16:654\u201361.","journal-title":"J Atheroscler Thromb"},{"key":"1684_CR33","first-page":"CD012735","volume":"6","author":"SP Adams","year":"2020","unstructured":"Adams SP, Alaeiilkhchi N, Wright JM. Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020;6:CD012735.","journal-title":"Cochrane Database Syst Rev"},{"key":"1684_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"K Yokote","year":"2008","unstructured":"Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345\u201352.","journal-title":"Atherosclerosis"},{"key":"1684_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijcard.2020.01.006","volume":"305","author":"M Moroi","year":"2020","unstructured":"Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139\u201346.","journal-title":"Int J Cardiol"},{"key":"1684_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","volume":"27","author":"M Casula","year":"2017","unstructured":"Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27:396\u2013406.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1684_CR37","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","volume":"38","author":"N Hagiwara","year":"2017","unstructured":"Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264\u201376.","journal-title":"Eur Heart J"},{"key":"1684_CR38","first-page":"2302","volume":"23","author":"XY Miao","year":"2019","unstructured":"Miao XY, Liu HZ, Jin MM, Sun BR, Tian H, Li J, et al. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2019;23:2302\u201310.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10349","key":"1684_CR39","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, RACING investigators, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390.","journal-title":"Lancet"},{"key":"1684_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000134","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhan S, Du H, Li J, Khan SU, Aertgeerts B, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJMED. 2022. https:\/\/doi.org\/10.1136\/bmjmed-2022-000134.","journal-title":"BMJMED"},{"key":"1684_CR41","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00380-018-1319-x","volume":"34","author":"A Nakamura","year":"2019","unstructured":"Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, Nozaki E. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2019;34:916\u201325.","journal-title":"Heart Vessels"},{"key":"1684_CR42","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","volume":"5","author":"M Banach","year":"2020","unstructured":"Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5:1124\u201335.","journal-title":"JAMA Cardiol"},{"key":"1684_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593\u2013603.","journal-title":"Eur J Prev Cardiol"},{"key":"1684_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"key":"1684_CR45","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","volume":"24","author":"LA Leiter","year":"2022","unstructured":"Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022;24:868\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"1684_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19:128.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR47","doi-asserted-by":"publisher","first-page":"e1003121","DOI":"10.1371\/journal.pmed.1003121","volume":"17","author":"AFG Cicero","year":"2020","unstructured":"Cicero AFG, Fogacci F, Hernandez AV, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17:e1003121.","journal-title":"PLoS Med"},{"key":"1684_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","volume":"14","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14:649-659.e6.","journal-title":"J Clin Lipidol"},{"key":"1684_CR49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","volume":"16","author":"U Laufs","year":"2022","unstructured":"Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, et al. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022;16:286\u201397.","journal-title":"J Clin Lipidol"},{"key":"1684_CR50","first-page":"180","volume":"31","author":"J Zhang","year":"2018","unstructured":"Zhang J, Tecson KM, Rocha NA, McCullough PA. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. Proc (Bayl Univ Med Cent). 2018;31:180\u20134.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"1684_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-0991-1","volume":"19","author":"HM Colhoun","year":"2020","unstructured":"Colhoun HM, Leiter LA, M\u00fcller-Wieland D, Cariou B, Ray KK, Tinahones FJ, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovasc Diabetol. 2020;19:14.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2020.08.018","volume":"134","author":"SA Khan","year":"2020","unstructured":"Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol. 2020;134:69\u201373.","journal-title":"Am J Cardiol"},{"key":"1684_CR53","first-page":"A11143","volume":"144","author":"LA Leiter","year":"2021","unstructured":"Leiter LA, Kallend DG, Koenig W, Landmesser U, Ray KK, Schwartz GG, et al. Efficacy and safety of inclisiran by baseline body mass index: a post hoc pooled analysis of the ORION-9, ORION-10 and ORION-11 phase III randomized controlled trials. Circulation. 2021;144:A11143.","journal-title":"Circulation"},{"key":"1684_CR54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/phar.2635","volume":"41","author":"AH Talasaz","year":"2021","unstructured":"Talasaz AH, Ho AJ, Bhatty F, Koenig RA, Dixon DL, Baker WL, Van Tassell BW. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy. 2021;41:1009\u201323.","journal-title":"Pharmacotherapy"},{"key":"1684_CR55","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1684_CR56","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, ODYSSEY OUTCOMES Committees and Investigators, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1684_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","volume":"21","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovasc Diabetol. 2022;21:107.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR58","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109\u201319.","journal-title":"Circulation"},{"key":"1684_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99\u2013109.","journal-title":"Atherosclerosis"},{"key":"1684_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-020-01002-x","volume":"19","author":"L Zhu","year":"2020","unstructured":"Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020;19:28.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR61","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc17-0968","volume":"41","author":"C Koopal","year":"2018","unstructured":"Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC. Predicting the effect of fenofibrate on cardiovascular risk for individual patients with type 2 diabetes. Diabetes Care. 2018;41:1244\u201350.","journal-title":"Diabetes Care"},{"issue":"1","key":"1684_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 2021;20(1):96.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1684_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-020-01132-2","volume":"19","author":"M Yoshida","year":"2020","unstructured":"Yoshida M, Nakamura K, Miyoshi T, Yoshida M, Kondo M, Akazawa K, et al. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl\/salt-sensitive rats fed a high-salt and high-fat diet. Cardiovasc Diabetol. 2020;19(1):149.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR64","unstructured":"KOWA to Discontinue K-877 (Pemafibrate) \"PROMINENT\" cardiovascular outcomes study. https:\/\/www.prnewswire.com\/. Accessed 8 Apr 2022."},{"key":"1684_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322.","journal-title":"N Engl J Med"},{"key":"1684_CR66","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet"},{"issue":"2","key":"1684_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5114\/aoms.2020.93253","volume":"16","author":"B Solnica","year":"2020","unstructured":"Solnica B, Sygitowicz G, Sitkiewicz D, Cybulska B, J\u00f3\u017awiak J, Odrow\u0105\u017c-Sypniewska G, Banach M. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020;16(2):237\u201352.","journal-title":"Arch Med Sci"},{"issue":"1","key":"1684_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","volume":"20","author":"AJ Lorenzatti","year":"2021","unstructured":"Lorenzatti AJ, Monsalvo ML, L\u00f3pez JAG, Wang H, Rosenson RS. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovasc Diabetol. 2021;20(1):94.","journal-title":"Cardiovasc Diabetol"},{"key":"1684_CR69","doi-asserted-by":"publisher","first-page":"200107","DOI":"10.1016\/j.ijcrp.2021.200107","volume":"11","author":"S Surma","year":"2021","unstructured":"Surma S, Roma\u0144czyk M, Filipiak KJ. Evinacumab\u2014the new kid on the block. Is it important for cardiovascular prevention? Int J Cardiol Cardiovasc Risk Prev. 2021;11:200107.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"1684_CR70","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2021.0006","author":"S Surma","year":"2021","unstructured":"Surma S, Roma\u0144czyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021. https:\/\/doi.org\/10.5603\/CJ.a2021.0006.","journal-title":"Cardiol J"},{"key":"1684_CR71","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2215\/CJN.16751020","volume":"16","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin J Am Soc Nephrol. 2021;16:705\u201316.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1684_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab350","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. CETP-inhibitors: from HDL-C to LDL-C lowering agents? Cardiovasc Res. 2021. https:\/\/doi.org\/10.1093\/cvr\/cvab350.","journal-title":"Cardiovasc Res"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01684-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01684-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T13:09:47Z","timestamp":1669640987000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01684-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01684-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed and approved the final version of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB: speakers bureau: Amgen, Herbapol, Kogen, KRKA, Polpharma, Mylan\/Viatris, Novartis, Novo-Nordisk, Sanofi-Aventis, Teva, Zentiva; consultant to Abbott Vascular, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, NewAmsterdam, Novartis, Polfarmex, Sanofi-Aventis; Grants from Amgen, Mylan\/Viatris, Sanofi and Valeant; CMO at the Nomi Biotech Corporation; NK: has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, Boehringer Ingelheim, Elpen, Novartis, Novo Nordisk, Sanofi, Servier, Viatris, Vianex and WinMedica; PEP: owns four shares in AstraZeneca PLC and has received honoraria and\/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, Sanofi; ZR has received honoraria and participated in trials sponsored by Novartis, Arrowhead; MR: has given lectures, received honoraria, and research support, and participated in conferences, advisory boards, and clinical trials sponsored by Amgen, Astra Zeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mediately, Mylan, Merck Sharp and Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. All other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}